Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07846891
Active, not recruiting Phase 4

Low Level Laser Therapy With Injectable Platelet Rich Fibrin in Management of Oral Lichen Planus

NCT07846891 · tracked via the Priya Life Science Egypt tracker
Sponsor
Ain Shams University
Phase
Phase 4
Started
2026-03-15
Last updated
2026-09-29

Condition(s) studied

Oral Lichen Planus

Investigational drug(s) / intervention(s)

Injectable Platelet Rich FibrinLow Level Laser TherapyTriamcinolone acetonide (injection) →

Injectable Platelet Rich Fibrin: Injectable Platelet Rich Fibrin (i- PRF) is a variant of PRF, a liquid blood derivative produced by using blood without anticoagulant or artificial biochemical modifications centrifuged at 700 rpm (60 g) for 3 mins in plastic tubes without any coatings.

Low Level Laser Therapy: Low Level Laser Therapy (LLLT) is a non invasive treatment, that emits short wavelength red or infrared light between (500-1100 nm) with a low water absorption. The bio stimulatory effect of laser irradiation results in physiological, metabolic, and functional changes in living microorganisms.

Triamcinolone acetonide (injection): Topical corticosteroid

Study summary

The Injectable PRF (i-PRF) is a variant of PRF, which is a liquid blood derivative rich in leukocytes and acts as a growth factor release, with its potential anti-inflammatory role, it may alleviate the symptoms of OLP.

Low Level Laser Therapy (LLLT) emits short wavelength red or infrared light between (500-1100 nm) with a low water absorption. This light can reach a depth of 3 mm to 15 mm in both soft and hard tissues, the biostimulatory effect of laser irradiation results in physiological, metabolic, and functional changes in living microorganisms. The investigators compared the clinical effectiveness of LLLT combined with (i-PRF) to the application of (i-PRF) alone and to that of topical corticosteroid regimen in symptomatic OLP and investigated therapeutic mechanism by examining treatment effect on expression of Tumor necrosis factor alpha (TNF-alpha) and Vascular endothelial growth factor (VEGF) in salivary samples from OLP patients.

Eligibility

Sex
ALL
Min age
40 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: Clinically and histologically proven painful Bullous/ erosive or atrophic forms of OLP. Exclusion Criteria: 1- History of drug induced lichenoid lesions. 2. Presence of systemic conditions as; serious active or recurrent infections, malignancy, diabetes mellitus, hypertension, or significant heart, liver, or renal diseases. 3\. Smoking. 4. Pregnancy or breast-feeding. 5. Loss of pliability or flexibility in the tissues involved by the oral lesions of lichen planus. 6\. Histological signs of epithelial dysplasia or lichenoid lesions within the biopsied sites. 7\. Refusing to participate in the study. 8. Vulnerable groups (handicapped).

Primary outcome measure(s)

  • Clinical evaluation — At baseline and once weekly for 1 month (treatment period).
    Healing potential regarding the size of OLP lesions: 0: represented no lesion/normal mucosa 1. mild white striae/no erythematous area 2. white striae with atrophic area less than 1 cm2 3. white striae with atrophic area more than 1 cm2 4. white striae with erosive area less than 1 cm2 5. white striae with erosive area more than 1 cm2

Trial sites (2)

FacilityCityRegionStatus
Faculty of Dentistry, Ain Shams University Cairo Cairo Governorate
Faculty of Dentistry, Ain Shams University Cairo Egypt

More Ain Shams University trials in Egypt

Intra-ureteric Aminophylline Instillation on Flexible Ureteroscopy Procedure Recruiting
3D Analysis of Soft Tissue Healing After Immediate Implant Placement Using PRF Vs HAM Active, not recruiting
Association Between Plasma D Dimer in Adult CAP and Severity of Inflammatory Response and Survival Recruiting
Efficacy of Ultrasound Guided Erector Spinae Plane Block Versus Ultrasound Guided Serratus Anterior Plane Block for Postoperative Pain Control Following Video-assisted Thoracoscopic Surgeries (VATS): Randomized Control Trial Recruiting
Effect of Kangaroo Mother Care on Energy Utilization in Preterm Neonates Active, not recruiting

Other trials for the same condition

Thyme Honey for Management of Oral Lichen Planus Enrolling by invitation
Effect of Topical Bromelain Versus Topical Corticosteroids in the Management of Oral Lichen Planus Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07846891 on ClinicalTrials.gov ↗ ← All trials in Egypt